ADC Therapeutics (ADCT) Notes Payables (2022 - 2023)

ADC Therapeutics has disclosed Notes Payables across 2 years of filings, most recently posting $14.3 million for Q3 2023.

• In Q3 2023, Notes Payables rose 14.63% year-over-year to $14.3 million; the TTM figure through Sep 2023 stood at $14.3 million (up 14.63% YoY), while the FY2022 annual figure was $12.5 million, changed N/A from the prior year.
• Notes Payables came in at $14.3 million for Q3 2023 at ADC Therapeutics, up from $13.9 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $14.3 million in Q3 2023 to a low of $12.5 million in Q4 2022.